The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer.
It’s an exciting time for research into high-risk neuroblastoma. Over the past year, multiple trials testing new treatments showed promising results, and in 2024, new…
Run the London Marathon for the Institute of Cancer Research and raise money for our life-saving research. Sign up today.
A Watford cancer survivor will take on the London Marathon this weekend in memory of two friends lost to the disease.
Help Rachel Talbot raise money to support The Institute of Cancer Research (ICR)
Help Susan Farrow raise money to support The Institute of Cancer Research (ICR)
As a fit and healthy former firefighter, Harry Hall didn’t think there was anything to worry about when he developed a lump in his neck.…
Nature Cancer – Lawson et al. show that genetic inactivation of Phd1 or Phd2 hinders progression of AML and compromises leukemic stem cells. They develop…
Scientists have uncovered a promising treatment strategy for an aggressive type of leukaemia – through targeting the enzymes that cells normally use to sense and…
Other London events Please note that this event takes place on the first floor, we’ re sorry there is no step-free access. The Green Man,…
Other London events Please note that this event takes place on the first floor and has no step-free access. The Prince Albert Battersea, 85 Albert…
